A Phase 3 interventional study of warfarin and apixaban in Atrial Fibrillation and Atrial Flutter, sponsored by Bristol-Myers Squibb. Completed at 1,113 sites in 41 countries. Per ClinicalTrials.gov, last updated 2018-07-03.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing apixaban in Atrial Fibrillation — 11 open to participants now, 12 under way, 4 of them phase 3. apixaban · Atrial Fibrillation.
Among the 31 studies testing apixaban in Atrial Fibrillation, this one has the largest enrollment, is the only one that started in 2006, is one of 12 in phase 3, and was the 1st registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →11 of the 31 studies testing apixaban in Atrial Fibrillation are open now, in 10 countries. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
VA Office of Research and Development · Sites in United States
Ages 22+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 65+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 19–80
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20,976 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 586 across the 31 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 31 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
33 studies in Atrial Fibrillation by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 30 finished, 4 (13%) have results posted.
Among the 33 studies in Atrial Fibrillation by Bristol-Myers Squibb, this one has the largest enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2006, is one of 3 in phase 3, and was the 2nd registered.
Bristol-Myers Squibb’s Atrial Fibrillation studies by the year they started, since 2006.
2 of the studies testing apixaban in Atrial Fibrillation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT03129490Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies testing apixaban in Atrial Fibrillation, from their registry updates:
Among Bristol-Myers Squibb’s 33 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: warfarin
Drug: apixaban
Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period
All suspected efficacy events were adjudicated by the Central Events Committee (CEC). Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
Time frame: Time to first event in "Intended Treatment Period": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding).
Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period
Rate=Number of adjudicated stroke or SE events per 100 patient years. Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.
Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Rate of Adjudicated Major (ISTH) Bleed Events During Treatment Period
Rate=number of adjudicated major (ISTH) bleed events per 100 patient years. ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.
Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Number of Participants With Events of All-Cause Death During the Intended Treatment Period
Death was defined as all-cause mortality. All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).
Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Rate of Adjudicated All-Cause Death During the Intended Treatment Period
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).
Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), and Myocardial Infarction (MI) (as Individual Endpoints) During the Intended Treatment Period
Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1.
Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), Myocardial Infarction (MI) and All-Cause Death (ACD) (as Composite Endpoints) During the Intended Treatment Period
Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. For description of ACD, see Outcome Measure 5.
Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Number of Warfarin/Vitamin K Antagonist (VKA) Naive Participants With Composite Stroke / Systemic Embolism (SE) / Major Bleeding During the Intended Treatment Period
For descriptions of Stroke and SE, see Outcome Measure 1. For description of Major bleeding, see Outcome Measure 3.
Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Rate of Composite Stroke / Systemic Embolism / Major Bleeding in Warfarin/Vitamin K Antagonist (VKA) Naive Participants During the Intended Treatment Period
Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period
Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death. CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy.
Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Rate of Events of Major or Clinically Relevant Non-Major (CRNM) Bleed During Treatment Period
Rate=number of major or CRNM bleed events per 100 patient years. Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death. CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy.
Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Number of Participants With All Bleeding Events During Treatment Period
All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.
Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Rate of All Bleeding Events During Treatment Period
Rate=number of all bleeding events per 100 patient years. "All bleeding events" include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.
Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Number of Participants With Adverse Events (AEs), Bleeding AEs, Serious Adverse Events (SAEs), Discontinuations Due to AEs, or Deaths During the Treatment Period
AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD). SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD. Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD. Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued. Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD.
Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Rate of Adjudicated Bleeding Endpoints Per Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) During the Treatment Period
Rate=number of adjudicated GUSTO bleeding events per 100 patient years. GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention. GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise.
Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Rate of Adjudicated Bleeding Endpoints Per Thrombolysis in Myocardial Infarction (TIMI) During the Treatment Period
Rate=number of adjudicated TIMI bleeding events per 100 patient years. TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions. Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions.
Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Number of Participants With Net-Clinical Benefit During Treatment Period
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding.
Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Rate of Net-Clinical Benefit During Treatment Period
Rate=number of events of net-clinical benefit per 100 patient years. Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding
Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
| Milestone | Apixaban | Warfarin |
|---|---|---|
| Started | 9120 | 9081 |
| Completed | 6810 | 6588 |
| Not completed | 2310 | 2493 |
| Withdrew: Death | 331 | 349 |
| Withdrew: Adverse event | 679 | 738 |
| Withdrew: Withdrawal by subject | 921 | 989 |
| Withdrew: Lost to follow-up | 51 | 39 |
| Withdrew: Poor/noncompliance | 57 | 77 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Subject no longer meets study criteria | 87 | 100 |
| Withdrew: Administrative reason by sponsor | 11 | 8 |
| Withdrew: Physician refused to continue treatment | 81 | 89 |
| Withdrew: Other reason | 80 | 92 |
| Withdrew: Not reported | 11 | 12 |
All suspected efficacy events were adjudicated by the Central Events Committee (CEC). Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
| participants | Apixaban | Warfarin |
|---|---|---|
| Ischemic or Unspecified Stroke | 159 | 173 |
| Hemorrhagic Stroke | 38 | 76 |
| Systemic Embolism | 15 | 16 |
Rate=Number of adjudicated stroke or SE events per 100 patient years. Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
| Number of events per 100 patient years | Apixaban | Warfarin |
|---|---|---|
| Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period | 1.27 | 1.60 |
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.
| participants | Apixaban | Warfarin |
|---|---|---|
| Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period | 327 | 462 |
Rate=number of adjudicated major (ISTH) bleed events per 100 patient years. ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.
| Number of events per 100 patient years | Apixaban | Warfarin |
|---|---|---|
| Rate of Adjudicated Major (ISTH) Bleed Events During Treatment Period | 2.13 | 3.09 |
Death was defined as all-cause mortality. All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).
| participants | Apixaban | Warfarin |
|---|---|---|
| Number of Participants With Events of All-Cause Death During the Intended Treatment Period | 603 | 669 |
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).
| Number of events per 100 patient years | Apixaban | Warfarin |
|---|---|---|
| Rate of Adjudicated All-Cause Death During the Intended Treatment Period | 3.52 | 3.94 |
Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1.
| Number of events per 100 patient years | Apixaban | Warfarin |
|---|---|---|
| Ischemic or Unspecified Stroke (n=162, 175) | 0.97 | 1.05 |
| Hemorrhagic Stroke (n=40, 78) | 0.24 | 0.47 |
| Systemic Embolism (n=15, 17) | 0.09 | 0.10 |
| Myocardial Infarction (n=90, 102) | 0.53 | 0.61 |
Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. For description of ACD, see Outcome Measure 5.
| Number of events per 100 patient years | Apixaban | Warfarin |
|---|---|---|
| Stroke / SE / Major Bleeding (n=521, 666) | 3.17 | 4.11 |
| Stroke / SE / All-Cause Death (ACD) (n=752, 837) | 4.49 | 5.04 |
| Stroke / SE / Major Bleeding / ACD (n=1009, 1168) | 6.13 | 7.20 |
| Stroke / SE / MI / ACD (n=810, 906) | 4.85 | 5.49 |
| Ischemic or Unspecified Stroke / ACD (n=725, 796) | 4.32 | 4.78 |
| Hemorrhagic Stroke / ACD (n=622, 703) | 3.68 | 4.20 |
| SE / ACD (n=613, 679) | 3.63 | 4.05 |
| MI / ACD (n=663, 740) | 3.93 | 4.43 |
For descriptions of Stroke and SE, see Outcome Measure 1. For description of Major bleeding, see Outcome Measure 3.
| participants | Apixaban | Warfarin |
|---|---|---|
| Number of Warfarin/Vitamin K Antagonist (VKA) Naive Participants With Composite Stroke / Systemic Embolism (SE) / Major Bleeding During the Intended Treatment Period | 229 | 285 |
| Number of events per 100 patient years | Apixaban | Warfarin |
|---|---|---|
| Rate of Composite Stroke / Systemic Embolism / Major Bleeding in Warfarin/Vitamin K Antagonist (VKA) Naive Participants During the Intended Treatment Period | 3.21 | 4.06 |
AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD). SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD. Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD. Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued. Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD.
| participants | Apixaban | Warfarin |
|---|---|---|
| AE | 7406 | 7521 |
| SAE | 3182 | 3302 |
| Bleeding AE | 2288 | 2961 |
| Discontinuations due to AE | 688 | 758 |
| Deaths | 429 | 468 |
Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death. CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy.
| participants | Apixaban | Warfarin |
|---|---|---|
| Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period | 613 | 877 |
Rate=number of major or CRNM bleed events per 100 patient years. Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death. CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy.
| number of events / 100 patient years | Apixaban | Warfarin |
|---|---|---|
| Rate of Events of Major or Clinically Relevant Non-Major (CRNM) Bleed During Treatment Period | 4.07 | 6.01 |
All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.
| participants | Apixaban | Warfarin |
|---|---|---|
| Number of Participants With All Bleeding Events During Treatment Period | 2356 | 3060 |
Rate=number of all bleeding events per 100 patient years. "All bleeding events" include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.
| number of events per 100 patient years | Apixaban | Warfarin |
|---|---|---|
| Rate of All Bleeding Events During Treatment Period | 18.08 | 25.82 |
Rate=number of adjudicated GUSTO bleeding events per 100 patient years. GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention. GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise.
| Number of events per 100 patient years | Apixaban | Warfarin |
|---|---|---|
| Severe (n=80, 172)) | 0.52 | 1.13 |
| Severe or Moderate (n=199, 328) | 1.29 | 2.18 |
Rate=number of adjudicated TIMI bleeding events per 100 patient years. TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions. Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions.
| Number of events per 100 patient years | Apixaban | Warfarin |
|---|---|---|
| Major (n=148, 256) | 0.96 | 1.69 |
| Major or Minor (n=239, 370) | 1.55 | 2.46 |
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding.
| participants | Apixaban | Warfarin |
|---|---|---|
| Number of Participants With Net-Clinical Benefit During Treatment Period | 459 | 608 |
Rate=number of events of net-clinical benefit per 100 patient years. Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding
| Number of events per 100 patient years | Apixaban | Warfarin |
|---|---|---|
| Rate of Net-Clinical Benefit During Treatment Period | 3.01 | 4.09 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Warfarin | — | 3,182/9,088 (35%) | 3,876/9,088 (42.6%) |
| Apixaban | — | 3,302/9,052 (36.5%) | 4,071/9,052 (45%) |
| Event | Warfarin | Apixaban |
|---|---|---|
| Cardiac failureCardiac disorders | 310/9088 | 301/9052 |
| Atrial fibrillationCardiac disorders | 301/9088 | 287/9052 |
| PneumoniaInfections and infestations | 202/9088 | 231/9052 |
| Cardiac failure congestiveCardiac disorders | 171/9088 | 175/9052 |
| Angina unstableCardiac disorders | 112/9088 | 87/9052 |
| Ischaemic strokeNervous system disorders | 91/9088 | 76/9052 |
| Myocardial infarctionCardiac disorders | 80/9088 | 63/9052 |
| SyncopeNervous system disorders | 79/9088 | 49/9052 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 68/9088 | 76/9052 |
| Chest painGeneral disorders | 43/9088 | 72/9052 |
| Event | Warfarin | Apixaban |
|---|---|---|
| NasopharyngitisInfections and infestations | 763/9088 | 779/9052 |
| DizzinessNervous system disorders | 654/9088 | 702/9052 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 547/9088 | 666/9052 |
| Oedema peripheralGeneral disorders | 607/9088 | 661/9052 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 583/9088 | 633/9052 |
| DiarrhoeaGastrointestinal disorders | 580/9088 | 581/9052 |
| CoughRespiratory, thoracic and mediastinal disorders | 493/9088 | 505/9052 |
| Back painMusculoskeletal and connective tissue disorders | 428/9088 | 502/9052 |
| Urinary tract infectionInfections and infestations | 471/9088 | 501/9052 |
| BronchitisInfections and infestations | 473/9088 | 493/9052 |
Randomized participants
| Age, Continuous(years) | Apixaban | Warfarin | Total |
|---|---|---|---|
| Mean | 69.1 ± 9.61 | 69.0 ± 9.74 | 69.1 ± 9.68 |
| Age, Customized(Participants) | Apixaban | Warfarin | Total |
|---|---|---|---|
| <65 years | 2731 | 2740 | 5471 |
| Between 65 and 75 years | 3539 | 3513 | 7052 |
| >=75 years | 2850 | 2828 | 5678 |
| Sex: Female, Male(Participants) | Apixaban | Warfarin | Total |
|---|---|---|---|
| Female | 3234 | 3182 | 6416 |
| Male | 5886 | 5899 | 11785 |
| Race/Ethnicity, Customized(Participants) | Apixaban | Warfarin | Total |
|---|---|---|---|
| White (European) | 5440 | 5366 | 10806 |
| White (Middle Eastern or North African) | 59 | 66 | 125 |
| White (Other White) | 2037 | 2060 | 4097 |
| White (Not Reported) | 0 | 1 | 1 |
| Black / African American | 125 | 102 | 227 |
| Asian (Asian Indian) | 307 | 312 | 619 |
| Asian (Chinese) | 536 | 536 | 1072 |
| Asian (Japanese) | 164 | 180 | 344 |
| Asian (Other Asian) | 303 | 304 | 607 |
| American Indian / Alaska Native | 26 | 24 | 50 |
| Native Hawaiian / Other Pacific Islander | 2 | 2 | 4 |
| Other | 121 | 127 | 248 |
| Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Apixaban | Warfarin | Total |
|---|---|---|---|
| Hispanic / Latino | 1808 | 1803 | 3611 |
| Not Hispanic / Latino | 7312 | 7276 | 14588 |
| Not Reported | 0 | 2 | 2 |
| Female Age Category(Participants) | Apixaban | Warfarin | Total |
|---|---|---|---|
| <=50 years | 81 | 88 | 169 |
| >50 years | 3153 | 3094 | 6247 |
| not applicable (male) | 5886 | 5899 | 11785 |
| Apixaban/Matching Placebo Dose at Randomization(Participants) | Apixaban | Warfarin | Total |
|---|---|---|---|
| 2.5 mg twice daily (BID) | 428 | 403 | 831 |
| 5.0 mg BID | 8692 | 8678 | 17370 |
| Risk Factor at Enrollment: Age >= 75 Years(Participants) | Apixaban | Warfarin | Total |
|---|---|---|---|
| >=75 years | 2850 | 2828 | 5678 |
| <75 years | 6270 | 6253 | 12523 |
7 further baseline measures are reported on the registry.
Showing the first 100 of 1,113 sites across 41 countries. Choose a country and city above to see the rest.
Ran from Dec 2006 to primary completion in May 2011, 52 months.
Results were first posted in Apr 2013, 1 year 11 months after primary completion.
Of 83 phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 52 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban